

[Paclitaxel](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01CD01](#)

Indication

Malignant neoplasms of nasopharynx ICD11 code: [2C3B.Z](#)

INN

Paclitaxel

Medicine type

Chemical agent

List type

Complementary

Formulations

**Parenteral > General injections > IV:** 6 mg per mL

EML status history

First added in 2015 ([TRS 994](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Paclitaxel](#)

[DrugBank](#)

[Paclitaxel](#)

Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for paclitaxel on the complementary list of the EML for use in treatment protocols for nasopharyngeal cancer was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for nasopharyngeal cancer is attached.